Abstract
Four different approaches have been reviewed herein: i) nucleoside analogs as mock agents of the reverse transcriptase (hTERT) catalytic site, ii) miscellaneous molecules with unknown mechanism(s) of action, iii) inhibitors of upstream processes of regulation of the hTERT subunit, iiii) immunotherapy against immunogenic hTERT- derived peptides.
Keywords: telomerase, anticancer drug, telomerase inhibitor, htert, mock agents, htert subunit
Mini-Reviews in Medicinal Chemistry
Title: Alternative Approaches to the Discovery and Development of Telomerase- Targeted Anticancer Drugs
Volume: 3 Issue: 1
Author(s): Sara Richter and Manlio Palumbo
Affiliation:
Keywords: telomerase, anticancer drug, telomerase inhibitor, htert, mock agents, htert subunit
Abstract: Four different approaches have been reviewed herein: i) nucleoside analogs as mock agents of the reverse transcriptase (hTERT) catalytic site, ii) miscellaneous molecules with unknown mechanism(s) of action, iii) inhibitors of upstream processes of regulation of the hTERT subunit, iiii) immunotherapy against immunogenic hTERT- derived peptides.
Export Options
About this article
Cite this article as:
Richter Sara and Palumbo Manlio, Alternative Approaches to the Discovery and Development of Telomerase- Targeted Anticancer Drugs, Mini-Reviews in Medicinal Chemistry 2003; 3 (1) . https://dx.doi.org/10.2174/1389557033405511
DOI https://dx.doi.org/10.2174/1389557033405511 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Moving Beyond VEGF for Anti-angiogenesis Strategies in Gynecologic Cancer
Current Pharmaceutical Design Eph Receptor Tyrosine Kinases in Tumor and Tumor Microenvironment
Current Pharmaceutical Design New Insight into P-Glycoprotein as a Drug Target
Anti-Cancer Agents in Medicinal Chemistry Patent Selections:
Recent Patents on Anti-Cancer Drug Discovery Mitochondrial Dysfunction and Targeted Drugs: A Focus on Diabetes
Current Pharmaceutical Design Natural Products as Anticancer Agents
Current Drug Targets Vascular Endothelial Growth Factor (VEGF) as a Target of Bevacizumab in Cancer: From the Biology to the Clinic
Current Medicinal Chemistry Bariatric Surgery - Effects on Obesity and Related co-Morbidities
Current Diabetes Reviews Heparan Sulphate Proteoglycans and Viral Vectors : Ally or Foe?
Current Gene Therapy Differences in the Expression Pattern of mRNA Protein SEMA3F in Endometrial Cancer <i>in vitro</i> under Cisplatin Treatment
Current Pharmaceutical Biotechnology Meet the Editorial Board
Current Drug Targets Vitamin D Receptor is a Novel Drug Target for Ovarian Cancer Treatment
Current Cancer Drug Targets Current Protein-based Anti-angiogenic Therapeutics
Mini-Reviews in Medicinal Chemistry Molecular Mechanisms Regulating Matrix Metalloproteinases
Current Topics in Medicinal Chemistry Achievements and Challenges of Proteomics in the Study of Rheumatoid Arthritis
Current Topics in Medicinal Chemistry Soy and Its Isoflavones: The Truth Behind the Science in Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Predicting Efficacy and Toxicity in the Era of Targeted Therapy: Focus on Anti-EGFR and Anti-VEGF Molecules
Current Drug Metabolism Estrogen Receptor Alpha: Impact of Ligands on Intracellular Shuttling and Turnover Rate in Breast Cancer Cells
Current Cancer Drug Targets Heterocyclic Moieties as HDAC Inhibitors: Role in Cancer Therapeutics
Mini-Reviews in Medicinal Chemistry Highlights on Medical Treatment of Uterine Fibroids
Current Pharmaceutical Design